4D Molecular Therapeutics, Inc. (FDMT) Financials
FDMT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 339.9 million | 32.1 million |
2023-09-30 | 361.6 million | 31.7 million |
2023-06-30 | 352.5 million | 725.3 million |
2023-03-31 | 244.0 million | 25.4 million |
FDMT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -25.2 million | 5.9 million |
2023-09-30 | -1.6 million | 4.6 million |
2023-06-30 | -22.9 million | 5.0 million |
2023-03-31 | -28.9 million | 4.2 million |
FDMT Net Income
No data available :(
FDMT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 288.2 million | - | 14.7 million |
2023-09-30 | 319.7 million | - | 15.2 million |
2023-06-30 | 310.3 million | - | 15.6 million |
2023-03-31 | 201.9 million | - | 15.7 million |
FDMT Shares Outstanding
FDMT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 549000 | 26.0 million | 10.6 million | - |
2023-09-30 | 405000 | 25.1 million | 9.1 million | - |
2023-06-30 | 805000 | 23.6 million | 8.8 million | - |
2023-03-31 | 1.0 million | 22.4 million | 8.0 million | - |
FDMT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | -19000 | 4.2 million |
2023-09-30 | 20.2 million | 1.4 million |
2023-06-30 | 239000 | 1.4 million |
2023-03-31 | 298000 | 1.4 million |
FDMT
Price: $26.38
52 week price:
Earnings Per Share: -2.58 USD
P/E Ratio: -12.19
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 192795
Market Capitalization: 1.3 billion